Tuberculosis For the treatment of tuberculosis,<unk>  is classified as a second-line drug, i.e. its use is only considered if one or more first-line drugs cannot be used. Hence,<unk>  is restricted for use only against multiple drug-resistant and extensively drug-resistant strains of M. tuberculosis. Another reason for limited use of this drug is the neurological side effects it causes, since it is able to penetrate into the central nervous system (CNS) and cause headaches, drowsiness, depression, dizziness, vertigo, confusion, paresthesias, dysarthria, hyperirritability, psychosis, convulsions, and shaking (tremors). Overdose of<unk>  may result in paresis, seizures, and coma, while alcohol consumption may increase the risk of seizures. Coadministration of pyridoxine can reduce the incidence of some of these CNS side effects (e.g. convulsions) caused by<unk> . Psychiatry A 2015 Cochrane review found no evidence of benefit in anxiety disorders as of 2015. Another review found preliminary evidence of benefit. Evidence for use in addiction is tentative but also unclear.
Cycloserine
Eflornithine
Galantamine
Plazomicin
Nalidixic acid
Nifurtimox/eflornithine
Cethromycin
Metamizole